[
  {
    "ts": null,
    "headline": "Banzai Announces Reverse Split",
    "summary": "SEATTLE, July 03, 2025 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced that effective at market open on July 8, 2025, the Company will effect a one-for-ten (1 for 10) reverse stock split of its outstanding Class A Common Stock and Class B Common Stock (together with the Class A Common Stock, the “Common Stock”). The reverse stock split is primar",
    "url": "https://finnhub.io/api/news?id=b465ad72a91d323605fa3fb93179cc552cea41a1de5bea868239e62229a7da36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751563800,
      "headline": "Banzai Announces Reverse Split",
      "id": 135739506,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "SEATTLE, July 03, 2025 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced that effective at market open on July 8, 2025, the Company will effect a one-for-ten (1 for 10) reverse stock split of its outstanding Class A Common Stock and Class B Common Stock (together with the Class A Common Stock, the “Common Stock”). The reverse stock split is primar",
      "url": "https://finnhub.io/api/news?id=b465ad72a91d323605fa3fb93179cc552cea41a1de5bea868239e62229a7da36"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher and Xcell Biosciences Partner to Advance TIL and Treg Cell Therapies",
    "summary": "Thermo Fisher Scientific Inc. (NYSE:TMO) ranks among the best CRISPR stocks to buy. On June 24, Thermo Fisher Scientific Inc. (NYSE:TMO) partnered with Xcell Biosciences, an instrumentation firm specializing in cell and gene therapy applications, to advance research on tumor-infiltrating lymphocytes (TILs) and regulatory T cells (Tregs). While an extensive amount of progress has been […]",
    "url": "https://finnhub.io/api/news?id=f4309c7b2c8389dc9af5a2295794b8f5f79ce0712cd0e19d08e5caf285d3074e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751548711,
      "headline": "Thermo Fisher and Xcell Biosciences Partner to Advance TIL and Treg Cell Therapies",
      "id": 135735820,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher Scientific Inc. (NYSE:TMO) ranks among the best CRISPR stocks to buy. On June 24, Thermo Fisher Scientific Inc. (NYSE:TMO) partnered with Xcell Biosciences, an instrumentation firm specializing in cell and gene therapy applications, to advance research on tumor-infiltrating lymphocytes (TILs) and regulatory T cells (Tregs). While an extensive amount of progress has been […]",
      "url": "https://finnhub.io/api/news?id=f4309c7b2c8389dc9af5a2295794b8f5f79ce0712cd0e19d08e5caf285d3074e"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher: A Quantitative Deep Dive Reveals Value But No Clear Uptrend",
    "summary": "TMO's financials show profitability but lack a clear positive trend, creating ongoing pressure on the stock price and limiting near-term upside. Click to read.",
    "url": "https://finnhub.io/api/news?id=06eee2d4d759c089ad09ee062ff33179d8e0540877b53e2b26fa3bf2a25eb080",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751536484,
      "headline": "Thermo Fisher: A Quantitative Deep Dive Reveals Value But No Clear Uptrend",
      "id": 135732926,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323872517/image_1323872517.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "TMO's financials show profitability but lack a clear positive trend, creating ongoing pressure on the stock price and limiting near-term upside. Click to read.",
      "url": "https://finnhub.io/api/news?id=06eee2d4d759c089ad09ee062ff33179d8e0540877b53e2b26fa3bf2a25eb080"
    }
  },
  {
    "ts": null,
    "headline": "Biopharmaceuticals Manufacturing Consumables Testing Market 2025-2030: Thermo Fisher Scientific, Danaher Corporation, and Merck Lead",
    "summary": "Demand for validated consumables and innovative testing methods like PCR and chromatography persists, driven by regulatory needs and environmental considerations Biopharmaceuticals Manufacturing Consumables Testing Market Biopharmaceuticals Manufacturing Consumables Testing Market Dublin, July 03, 2025 (GLOBE NEWSWIRE) -- The \"Biopharmaceuticals Manufacturing Consumables Testing Market by Product Type, Testing Type, Technology, Application, End User - Global Forecast to 2030\" has been added to R",
    "url": "https://finnhub.io/api/news?id=35ae3bcb67cc63684b6ccad404744c013d29cecce62d5329b4b9fd6c3d1318b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751530860,
      "headline": "Biopharmaceuticals Manufacturing Consumables Testing Market 2025-2030: Thermo Fisher Scientific, Danaher Corporation, and Merck Lead",
      "id": 135735821,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Demand for validated consumables and innovative testing methods like PCR and chromatography persists, driven by regulatory needs and environmental considerations Biopharmaceuticals Manufacturing Consumables Testing Market Biopharmaceuticals Manufacturing Consumables Testing Market Dublin, July 03, 2025 (GLOBE NEWSWIRE) -- The \"Biopharmaceuticals Manufacturing Consumables Testing Market by Product Type, Testing Type, Technology, Application, End User - Global Forecast to 2030\" has been added to R",
      "url": "https://finnhub.io/api/news?id=35ae3bcb67cc63684b6ccad404744c013d29cecce62d5329b4b9fd6c3d1318b3"
    }
  },
  {
    "ts": null,
    "headline": "Here's What to Expect From Thermo Fisher Scientific's Next Earnings Report",
    "summary": "Thermo Fisher Scientific is poised to release its second-quarter results later this month, and analysts project a single-digit earnings drop.",
    "url": "https://finnhub.io/api/news?id=8b2776add6e67c568e2219e5018e8a88237e9d08e00d9b5e837aef17dde6def7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751524974,
      "headline": "Here's What to Expect From Thermo Fisher Scientific's Next Earnings Report",
      "id": 135735823,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher Scientific is poised to release its second-quarter results later this month, and analysts project a single-digit earnings drop.",
      "url": "https://finnhub.io/api/news?id=8b2776add6e67c568e2219e5018e8a88237e9d08e00d9b5e837aef17dde6def7"
    }
  },
  {
    "ts": null,
    "headline": "Is Thermo Fisher A Buy? A Deep Dive Into Growth, Valuation, And Moat",
    "summary": "Thermo Fisher's strong economic moat, slowing growth, and fair valuation. Valuation is reasonable, trading near decade-low multiples. See more on TMO stock here.",
    "url": "https://finnhub.io/api/news?id=7f15fe109c322b0ea47bea00cd5756e39b0192f40789e4f2e3f1acb76f85f05b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751511235,
      "headline": "Is Thermo Fisher A Buy? A Deep Dive Into Growth, Valuation, And Moat",
      "id": 135723514,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1873437801/image_1873437801.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "Thermo Fisher's strong economic moat, slowing growth, and fair valuation. Valuation is reasonable, trading near decade-low multiples. See more on TMO stock here.",
      "url": "https://finnhub.io/api/news?id=7f15fe109c322b0ea47bea00cd5756e39b0192f40789e4f2e3f1acb76f85f05b"
    }
  }
]